Skip to main content
. 2024 Feb 3;30:100688. doi: 10.1016/j.lana.2024.100688

Fig. 2.

Fig. 2

(A) Prevalence of persistent COVID-19 symptoms amongst SARS-CoV-2 N-protein seropositive adults ≥20 years in ENSANUT 2022; and (B) prevalence of post-acute sequelae of SARS-CoV-2 symptoms (PASC) as identified by a PASC score ≥12 in the overall population, in SARS-CoV-2 N-protein seropositive adults and in individuals with COVID-19 previously diagnosed by a physician in the ENSANUT 2022 sample.